2024
The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils
Díaz-Varela M, Sanchez-Hidalgo A, Calderon-Copete S, Tacchini V, Shipley T, Ramírez G, Marquis J, Fernández O, Saravia N, Tacchini-Cottier F. The different impact of drug-resistant Leishmania on the transcription programs activated in neutrophils. IScience 2024, 27: 109773. PMID: 38711445, PMCID: PMC11070714, DOI: 10.1016/j.isci.2024.109773.Peer-Reviewed Original ResearchDrug-resistant parasitesDrug resistanceEffective control of infectionProduction of cytokinesDrug-resistant infectionsControl of infectionMyeloid recruitmentImmune microenvironmentChemokines CCL3Drug susceptibilityMyeloid cellsCCL3 levelsMouse modelNeutrophil subsetsDrug-resistant LeishmaniaNeutrophilsAntimicrobial controlImpaired abilityInfectionCCL3Neutrophil genesTranscriptional programsParasite strainsDrugParasitic diseases
2017
Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility
Barrera MC, Rojas LJ, Weiss A, Fernandez O, McMahon-Pratt D, Saravia NG, Gomez MA. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility. Acta Tropica 2017, 176: 355-363. PMID: 28843396, PMCID: PMC5633519, DOI: 10.1016/j.actatropica.2017.08.017.Peer-Reviewed Original ResearchConceptsLeishmania resistanceDrug susceptibilityDrug resistanceHost cell gene expressionClinical strainsCell gene expressionExpression of ABCA2THP-1 cellsPrimary human macrophagesLeishmania susceptibilityGene expressionAntimonial drugsCutaneous leishmaniasisInfected macrophagesLeishmania panamensisIntracellular amastigotesHuman macrophagesResistant strainsSusceptible parasitesAntimonialsIntracellular parasitesLeishmania speciesMacrophagesL. panamensisAQP-9
2006
Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection
Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. The Journal Of Infectious Diseases 2006, 193: 1375-1383. PMID: 16619185, DOI: 10.1086/503371.Peer-Reviewed Original ResearchConceptsTreatment failureMeglumine antimoniatePrimary resistanceAntimonial drugsSecondary resistanceDrug resistanceHuman Leishmania infectionsEffective immune responseAnthroponotic visceral leishmaniasisAmerican cutaneous leishmaniasisAntimonial therapyStandard treatmentCutaneous diseaseLeishmania infectionTherapeutic responseImmune responseCutaneous leishmaniasisVisceral leishmaniasisAnthroponotic transmissionResistant organismsEffective doseIntracellular amastigotesSusceptible strainsAntimoniatePatients
2003
Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002.
González IJ, Padilla JO, Giraldo LE, Saravia NG. Efficacy of amodiaquine and sulfadoxine/pyrimethamine in the treatment of malaria not complicated by Plasmodium falciparum in Nariño, Colombia, 1999-2002. Biomédica 2003, 23: 38-46. PMID: 12696398, DOI: 10.7705/biomedica.v23i1.1196.Peer-Reviewed Original ResearchConceptsSulfadoxine/pyrimethamineTreatment failureUncomplicated Plasmodium falciparum malariaCombination of amodiaquineEfficacy of amodiaquinePlasmodium falciparum malariaSP treatment failureModerate malaria transmissionAntimalarial drug resistanceTreatment of malariaFalciparum malariaAntimalarial treatmentTherapeutic failureAntimalarial resistanceCurrent doseAntimalarial efficacyMalaria transmissionPatientsAntimalarial drugsDrug resistanceAmodiaquinePlasmodium falciparumTreatment regimesMalariaEfficacy